Orchid AMS eyes Rs 300 cr turnover in 3 years; to step up fight against antimicrobial resistance

New Delhi : According to a high-ranking company official, Orchid Pharma's recently established antimicrobial solutions division aims to achieve a turnover of up to Rs 300 crore in the next three years with around 250 salespeople to address the issue of antimicrobial resistance in India. Orchid AMS aims to collaborate with approximately 2,500-3,000 hospitals and healthcare institutions over the next two to three years to establish successful antimicrobial stewardship programmes (AMSPs).

According to Rajnish Rohatgi, CEO of Orchid AMS, a division of Orchid Pharma, antimicrobial resistance is a significant healthcare challenge outside of hospitals due to the easy availability of medications without prescriptions, as well as antibiotics entering through poultry, fish, and crops. This is a massive problem. He stated that the launch of the new division was not just about making a business impact, but also about having a purpose beyond business and giving back to society in their own way by addressing this issue.

Orchid AMS intends to offer creative responses to antimicrobial resistance (AMR) and serve approximately 3,000 hospitals and healthcare facilities within the next 2-3 years. By the end of this year, sessions will be organized in 13 cities to connect with the healthcare community on AMR. When questioned about potential business prospects, Rohatgi mentioned that they aim to have a sales team of around 250 employees within three years and are striving for a turnover between Rs 250- Rs 300 crore.

Expanding on his statement, he mentioned that by FY25-26, their team is expected to grow to around 125 members, aiming for a division sales of around Rs 100 crore. Additionally, they plan to expand their reach to 2,000 hospitals nationwide by the end of FY26.A wide range of molecules will be introduced to 2,500 to 3,000 hospitals within the following three years. Rohatgi mentioned that distributors have already been assigned for important cities in North, West, and South India for the product launch. Phase II will still need to cover Central and East India.